Use the hyperlinks, where available to access additional clinical trial information.
Phase I, Open Label, Non-randomised, Non-comparative, Multi-center Study, Evaluating S65487, a Bcl-2 Inhibitor Intravenously Administered, in Patients With Relapse or Refractory Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
This study is designed in two parts: one part for dose escalation and one part for dose expansion. S65487 will be administered as single agent via intravenous infusion on a 3-week cycle. Once dose escalation is complete, dose expansion will commence at the maximum tolerated or recommended phase 2 dose.